<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":3498,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Pozen Inc. v. Par Pharmaceutical, Inc., 696 F.3d 1151, 104 U.S.P.Q.2d 1969 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document fluid'>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/81f7e21f769d735614e58c05e1fd6833'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/81f7e21f769d735614e58c05e1fd6833'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1IHGBK003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1IHGBK003">Previous Result: <span>Johnson v. City of Rock Island, Case No....</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1IHGBM003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1IHGBM003">Next Result: <span>Kleen Products, LLC v. Packaging Corp. o...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='Pozen Inc. v. Par Pharmaceutical, Inc., 696 F.3d 1151, 104 U.S.P.Q.2d 1969 (Fed. Cir. 2012), Court Opinion'>
Pozen Inc. v. Par Pharmaceutical, Inc., 696 F.3d 1151, 104 U.S.P.Q.2d 1969 (Fed. Cir. 2012),...
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Pozen Inc. v. Par Pharmaceutical, Inc., 696 F.3d 1151, 104 U.S.P.Q.2d 1969 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1IHF5K003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Pozen Inc. v. Par Pharmaceutical, Inc.</div>
<div class='displayCitation'>104 U.S.P.Q.2d 1969</div>
<div class='displayCitation'>2012 BL 251324</div>
<div class='displayCitation'>696 F.3d 1151</div>
<div class='displayCitation'>bna a0d4x0d6h8</div>
<div class='displayCitation'>wkffecase:26500698</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1IHF5K003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Pozen Inc. v. Par Pharmaceutical, Inc., 696 F.3d 1151, 104 U.S.P.Q.2d 1969 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Pozen Inc. v. Par Pharmaceutical, Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1IHF5K003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1IHF5K003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1IHF5K003" /><input id="title" name="title" type="hidden" value="Pozen Inc. v. Par Pharmaceutical, Inc., 696 F.3d 1151, 104 U.S.P.Q.2d 1969 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="81f7e21f769d735614e58c05e1fd6833" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1IHF5K003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%38%31f%37e%32%31f%37%36%39d%37%33%35%36%31%34e%35%38c%30%35e%31fd%36%38%33%33%2Fdocument%2FX%31IHF%35K%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/bcite/X1IHF5K003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/bcite/X1IHF5K003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/bcite/X1IHF5K003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/related_content/X1IHF5K003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=true;
  //]]>
</script>

<table cellpadding='0' cellspacing='0' class='hasSearchTerms ' id='fluidHolder'>
<tr>
<td align='right' class='fluidLeftColumn' valign='top' width='100%'>
<div class='documentContent hasSearchTerms ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1736749744131";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">696 F.3d 1151</div>
<div class="cite" data-cite-type="ReporterOfDecisions">104 U.S.P.Q.2d 1969</div>
<div class="cite" data-cite-type="DocketNumber">Nos. 2011-1584, 2011-1585, 2011-1586.</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 251324</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
POZEN INC., Plaintiff-Appellee, v. PAR PHARMACEUTICAL, INC.,
Defendant-Appellant, and Dr. Reddy's Laboratories, Inc.,
Defendant-Appellant, and Alphapharm Pty Ltd., Defendant-Appellant.
</center></p>
<hr align="center" width="65%">
<p><center>
Nos. 2011-1584, 2011-1585, 2011-1586.
</center></p>
<p><center>
September 28, 2012.
<span CLASS="page_no" data-cite="104 uspq 2d 1972" data-cite-type="ReporterOfDecisions" data-cite-pageno="1972" data-primary-citation="104 U.S.P.Q.2d 1969">[**1972]</span> </center></p>
<span CLASS="page_no" data-cite="696 f 3d 1152" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1152" data-primary-citation="696 F.3d 1151">[*1152]</span> <div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_931140" href="#headnote_ref_pq2-dec_931140">[1]</a> <span>Patentability/Validity &mdash; Construction of claims </span> <a href="http://www.bloomberglaw.com/document/1736749744131/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.03">&#9658;115.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patent construction &mdash; Claims &mdash; Broad or narrow </span> <a href="http://www.bloomberglaw.com/document/1736749744131/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=125.1303" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="125.1303">&#9658;125.1303</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patent construction &mdash; Claims &mdash; Defining terms </span> <a href="http://www.bloomberglaw.com/document/1736749744131/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=125.1305" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="125.1305">&#9658;125.1305</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnote_text">
Term &ldquo;concomitant administration,&rdquo;
in claims directed to method for treating migraines by combining drugs sumatriptan and naproxen, was properly applied to prior art references as requiring simultaneous, not sequential, administration of sumatriptan and naproxen, since parties agreed to construction of claim term &ldquo;concomitantly administering&rdquo; as meaning &ldquo;[g]iven in close enough temporal proximity to allow their individual therapeutic effects to overlap,&rdquo;
and agreed that &ldquo;unit dose&rdquo; limitation of claims means &ldquo;single drug administration entity(ies),&rdquo; and since term &ldquo;unit dose,&rdquo; when considered in context of claim language, necessarily limits concomitant administration to mean simultaneous administration, in that single drug administration entity cannot be administered in any other manner.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_931141" href="#headnote_ref_pq2-dec_931141">[2]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1736749744131/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnote_text">
Prior art epidemiological survey assessing various migraine treatments does not render obvious asserted claims directed to method for treating migraines by simultaneously combining sumatriptan and nonsteroidal anti-inflammatory naproxen in amounts effective to reduce migraine relapse or produce longer lasting efficacy compared to administration of either drug alone, even though survey contains entry for combination of sumatriptan and NSAIDs, since reference specifies only unsatisfactory results of monotherapy treatment, and does not indicate relative successes of various combination treatments, and since reference does not disclose whether combination of NSAIDs and sumatriptan reduced migraine relapse or produced longer lasting efficacy as required by claims, and does not disclose dosage of that combination treatment.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_931142" href="#headnote_ref_pq2-dec_931142">[3]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1736749744131/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Obviousness &mdash; Combining references </span> <a href="http://www.bloomberglaw.com/document/1736749744131/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0905" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0905">&#9658;115.0905</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_6" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_6" class="headnoteContent"></div>
<div class="headnote_text">
Prior art report on abortive migraine therapy, combined with secondary reference disclosing beneficial effects of sumatriptan on nausea, does not render obvious asserted claims directed to method for treating migraines by simultaneously combining sumatriptan and nonsteroidal anti-inflammatory naproxen in amounts effective to reduce migraine relapse or produce longer lasting efficacy compared to administration of either drug alone, since primary reference, which discloses administration of oral naproxen sodium plus metoclopramide plus ergotamine tartrate with caffeine, teaches each drug as having specific purpose, and since secondary reference teaches that antiemetics, such as metoclopramide and caffeine, are unnecessary with sumatriptan, but reference does not provide motivation to person of skill in art to substitute sumatriptan in place of metoclopramide, ergotamine, and caffeine, and does not teach remaining efficacy limitations of claims.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_931143" href="#headnote_ref_pq2-dec_931143">[4]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1736749744131/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_7" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_7" class="headnoteContent"></div>
<div class="headnote_text">
Prior art hospital patient records, showing that doctors prescribed daily dose of naproxen as prophylactic treatment and sumatriptan for treating acute migraines, do not render obvious asserted claims directed to method for treating migraines by simultaneously combining sumatriptan and nonsteroidal anti-inflammatory naproxen in amounts effective to reduce migraine relapse or produce longer lasting efficacy compared to administration of either drug alone, since one treating physician testified that he did not recall prescribing or administering sumatriptan and naproxen simultaneously, and records do not suggest that prescribed treatment produced longer lasting efficacy or reduced migraine relapse, and since one patient's prescription was soon changed to administration of sumatriptan and antidepressant, suggesting that sumatriptan/naproxen combination did not relieve migraine symptoms.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_931144" href="#headnote_ref_pq2-dec_931144">[5]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1736749744131/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_8" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_8" class="headnoteContent"></div>
<div class="headnote_text">
Prior art case report, which discloses that treating patient's acute migraine attacks with either nonsteroidal anti-inflammatories or sumatriptan was not beneficial, does not render obvious asserted claims directed to method for treating migraines by simultaneously combining sumatriptan and nonsteroidal anti-inflammatory naproxen in amounts effective to reduce migraine relapse or produce longer lasting efficacy compared to administration of either drug alone, since reference does not teach that combination of sumatriptan and naproxen provided migraine relief, but instead concludes that only effective treatment for patient was sumatriptan and acupuncture, and since reference discourages combining sumatriptan and naproxen to achieve claimed efficacy benefits, and therefore teaches away from claimed invention. </div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_931145" href="#headnote_ref_pq2-dec_931145">[6]</a> <span>Patentability/Validity &mdash; Construction of claims </span> <a href="http://www.bloomberglaw.com/document/1736749744131/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.03">&#9658;115.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_9" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_9" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Obviousness &mdash; Combining references </span> <a href="http://www.bloomberglaw.com/document/1736749744131/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0905" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0905">&#9658;115.0905</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_10" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_10" class="headnoteContent"></div>
<div class="headnote_text">
Asserted claims directed to method for treating migraines by combining triptan and nonsteroidal anti-inflammatory naproxen in multi-layer pharmaceutical tablet, in side-by-side arrangement such that dissolution of naproxen occurs independently of triptan, are not invalid for obviousness, even though multi-layer tablets were commonly used, since claimed dosage forms and specific tablet architecture were not obvious in light of cited combination of prior art references, and regardless of whether federal district court used, in its invalidity analysis, &ldquo;plain and ordinary&rdquo; meaning or &ldquo;narrow&rdquo; interpretation of &ldquo;independent dissolution&rdquo; element, presumption of validity afforded issued patents was not rebutted by clear and convincing evidence.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_931146" href="#headnote_ref_pq2-dec_931146">[7]</a> <span>Patentability/Validity &mdash; Specification &mdash; Written description </span> <a href="http://www.bloomberglaw.com/document/1736749744131/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.1103" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.1103">&#9658;115.1103</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_11" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_11" class="headnoteContent"></div>
<div class="headnote_text">
Asserted claims directed to therapeutic package for dispensing, to migraine patient, one or more unit doses containing sumatriptan and naproxen in specified amounts are not invalid on ground that limitations &ldquo;therapeutic package,&rdquo; &ldquo;finished pharmaceutical container,&rdquo; and &ldquo;said container further containing or comprising labeling directing the use of said package in the treatment of migraine&rdquo; lack adequate written description in specification, since claims disclose several dosage forms, including oral unit dosage, to teach treating migraines by concomitantly administering therapeutic amounts of sumatriptan and naproxen, since it is reasonable to conclude that person of ordinary skill in art would understand, based on disclosures, that pharmaceutical dosages are administered in containers or packages with labeling and inserts with dosage instructions, since U.S. Food and Drug Administration requires container labeling and information for prescription pharmaceutical products, and since, therefore, specification describes invention in such manner that claim terms at issue are understandable to person of ordinary skill.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_931147" href="#headnote_ref_pq2-dec_931147">[8]</a> <span>Infringement &mdash; Doctrine of equivalents &mdash; In general </span> <a href="http://www.bloomberglaw.com/document/1736749744131/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.0701" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.0701">&#9658;120.0701</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_12" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_12" class="headnoteContent"></div>
<div class="headnote_text">
Accused generic pharmaceutical products infringe, under doctrine of equivalents, asserted claims directed to method for treating migraines by combining triptan and nonsteroidal anti-inflammatory naproxen in multi-layer pharmaceutical tablet, in side-by-side arrangement such that dissolution of naproxen occurs &ldquo;independently&rdquo; of triptan, even though there is no direct evidence comparing dissolution rates of active agents in accused products to that of agents when taken alone, since infringement under doctrine of equivalents requires showing only that accused products perform substantially same function in substantially same way to achieve substantially same result as &ldquo;independent dissolution&rdquo; limitation, since expert testimony demonstrated that, in accused products, sumatriptan dissolves completely and independently from naproxen, and that naproxen dissolves completely and independently from sumatriptan, and since probative documentary evidence in record supports that testimony.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_931148" href="#headnote_ref_pq2-dec_931148">[9]</a> <span>Infringement &mdash; Doctrine of equivalents &mdash; In general </span> <a href="http://www.bloomberglaw.com/document/1736749744131/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=120.0701" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="120.0701">&#9658;120.0701</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_13" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_13" class="headnoteContent"></div>
<div class="headnote_text">
Doctrine of equivalents can apply to claims directed to method for treating migraines by combining triptan and nonsteroidal anti-inflammatory naproxen in multi-layer pharmaceutical tablet, wherein &ldquo;substantially all&rdquo; of triptan is in first layer of tablet, and &ldquo;substantially all&rdquo; of naproxen is in second, separate layer, even though &ldquo;substantially all&rdquo; language is qualitative measure, since agreed-on claim construction pulls directly from specification to give term quantitative definition of &ldquo;at least 90%, and preferably greater than 95%,&rdquo;
since application of doctrine of equivalents is not foreclosed with respect to ranges, and since patentee never stated that those figures should create absolute floor; accused generic pharmaceutical products infringe &ldquo;substantially all&rdquo; limitation under doctrine of equivalents, even though one layer in each of accused products contains both agents, since products are bilayer tablets with 100 percent of one agent in one layer, and 85 percent of second agent in second layer, and this structure is insubstantially different from bilayer tablet with 90 percent of total therapeutic agent present in tablet included in single layer, and since accused products do not constitute disclaimed &ldquo;admixtures,&rdquo;
in that substantially all of active agents are separated and segregated into two distinct layers, not blended or mixed.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the Eastern District of
Texas, Leonard Davis, J.
<span CLASS="page_no" data-cite="696 f 3d 1153" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1153" data-primary-citation="696 F.3d 1151">[*1153]</span> 
[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
</p></div>
<div id="para2" printdualcolumn="true"><p>
<span CLASS="page_no" data-cite="696 f 3d 1154" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1154" data-primary-citation="696 F.3d 1151">[*1154]</span> 
[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
</p></div>
<div id="para2" printdualcolumn="true"><p>
<span CLASS="page_no" data-cite="696 f 3d 1155" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1155" data-primary-citation="696 F.3d 1151">[*1155]</span> 
[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
</p></div>
<div id="para2" printdualcolumn="true"><p>
<span CLASS="page_no" data-cite="696 f 3d 1156" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1156" data-primary-citation="696 F.3d 1151">[*1156]</span> 
Stephen M. Hash, Vinson &amp; Elkins LLP, of Austin, TX, argued for
plaintiff-appellee. With him on the brief were Tracey B. Davies, Willem G.
Schuurman and Jennifer Librach Nail; and Stephanie Lollo Donahue and Rebecca
J. Cantor, of New York, NY.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Richard J. Berman, Arent Fox LLP, of Washington, DC, argued for
defendant-appellants Par Pharmaceutical, Inc. and Alphapharm Pty., Ltd. Of
counsel on the brief was Thomas J. Parker, Alston &amp; Bird, LLP, of New York,
NY. Of counsel for Par Pharmaceutical, Inc. were Taniel Ermano Anderson,
Timothy Bucknell, Aziz Burgy, Janine A. Carlan, Joshua T. Morris and Amy E.
Ligler Schoenhard. Of counsel for Alphapharm Pty.,' Ltd., was Natalie C.
Clayton, Alston &amp; Bird, LLP, of New York, NY.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Paul H. Kochanski, Lerner, David, Littenberg, Krumholz &amp; Mentlik, LLP, of
Westfield, NJ, argued for defendant-appellant, Dr. Reddy's Laboratories,
Inc. With him on the brief were Michael H. Teschner and Roy H. Wepner.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before NEWMAN, CLEVENGER, and WALLACH, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
WALLACH, Circuit Judge.
</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  INTRODUCTION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Opinion for the court filed by Circuit Judge WALLACH. Dissenting-in-part
opinion filed by Circuit Judge CLEVENGER.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Par Pharmaceutical, Inc. ("Par"), Alphapharm Pty Ltd. ("Alphapharm"), and
Dr. Reddy's Laboratories, Inc. ("DRL") (collectively "Appellants") appeal
from the final judgment of the United States District Court for the Eastern
District of Texas. Following a bench trial, the district court determined
that the asserted claims of <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">U.S. Patent No. 6,060,499</a> (filed Sept. 11, 1998)
(the "'<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a>"), <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3190C42I0J?jcsearch=usp%206586458&amp;summary=yes#jcite">U.S. Patent No. 6,586,458</a> (filed Apr. 27, 2000) (the
"'<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3190C42I0J?jcsearch=usp%206586458&amp;summary=yes#jcite">458 patent</a>"), and <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">U.S. Patent No. 7,332,183</a> (filed Dec. 22, 2003) (the
"'<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a>") (collectively "patents-in-suit") are not invalid as obvious
under <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEIVVE003?jcsearch=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>. The district court also found that the
patents-in-suit were infringed by Par and DRL's Abbreviated New Drug
Application ("ANDA") filings. As a result, Par and DRL were enjoined from
making, using, importing, selling or offering to sell their generic products
in the United States.<a HREF="#fn100" name="fnref_fn100">[fn1]</a> We affirm the district court's decision because
it did not err in finding the patents-in-suit not invalid and infringed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Pozen developed a method for treating migraines by combining two drugs,
sumatriptan and naproxen, in a single tablet. <i>Pozen Inc. v. Par Pharm.,</i>
<i>Inc.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20f%20supp%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d 789</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20f%20supp%202d%20789&amp;summary=yes#jcite">796</a> (E.D.Tex.2011). Sumatriptan, a 5-HT receptor
agonist, was developed in the late 1980s and is widely accepted as an
effective medicine for migraines, but it does not prevent the reoccurrence
of migraine symptoms. <i></i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id. at 797</a>. Naproxen is a well known nonsteroidal
<span CLASS="page_no" data-cite="696 f 3d 1157" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1157" data-primary-citation="696 F.3d 1151">[*1157]</span> 
anti-inflammatory drug ("NSAID"). <i></i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id. at 798</a>. Pozen, in partnership with
GlaxoSmithKline ("GSK"), markets a combination <span CLASS="page_no" data-cite="2012 bl 251324 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> of sumatriptan and naproxen
called Treximet&reg; and <span CLASS="page_no" data-cite="104 uspq 2d 1973" data-cite-type="ReporterOfDecisions" data-cite-pageno="1973" data-primary-citation="104 U.S.P.Q.2d 1969">[**1973]</span> holds three related patents relevant to this appeal.
<i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.</i> The `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a> claims a method of treating migraines comprising
co-timely administration of 5-HT agonists and long-acting NSAIDs. `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499
patent</a> col.111.13-17. The `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3190C42I0J?jcsearch=usp%206586458&amp;summary=yes#jcite">458 patent</a> is a continuation of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a>
and claims methods and compositions combining 5-HT agonists and long-acting
NSAIDs. `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3190C42I0J?jcsearch=usp%206586458&amp;summary=yes#jcite">458 patent</a> coll 11.18-20. The `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> claims a multilayer
pharmaceutical tablet with a triptan, such as sumatriptan, and a NSAID in
separate layers that dissolve independently. `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> col.111.54-57.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Pozen filed a New Drug Application ("NDA") to market Treximet&reg; and
obtained approval from the United States Food and Drug Administration
("FDA") on April 15, 2008. <i>Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 798</a>. Pozen listed the
patents-in-suit in its NDA as covering Treximet&reg;. The patents are included
in the FDA's Approved Drug. Products with Therapeutic Equivalence
Evaluations (known as "the Orange Book"), <i>see</i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(1)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(b)(1),
indicating they could be infringed by the unlicensed manufacture, use, or
sale of Treximet&reg;. <i>Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 798</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellants are generic pharmaceutical manufacturers who filed AND As with
the FDA seeking approval to market generic forms of Treximet&reg; before the
expiration of Pozen's patents. <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.; see</i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(b)(2)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(b)(2), <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)&amp;summary=yes#jcite">(j)(2)</a>.
Appellants filed their application certifying that the patents listed in the
Orange Book are "invalid or will not be infringed" by the generic products.
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEI5OQ003?jcsearch=21%20U.S.C.%20%20355(j)(2)(A)(vii)(IV)&amp;summary=yes#jcite">21 U.S.C. &sect; 355</a>(jX2)(A)(vii)(IV); <i>Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 798-99</a>; Such a
certification constitutes an artificial act of infringement.
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2); <i>Warner-Lambert Co. v. Apotex Corp.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">316 F.3d 1348</a>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X17O53QNB5G0?jcsearch=316%20f%203d%201348&amp;summary=yes#jcite">1365</a> (Fed.Cir.2003). Thereafter, Pozen filed complaints against Appellants
for infringement of claim 15 of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a>; claims 11, 12, 24, 26, 27,
29, and 30 of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3190C42I0J?jcsearch=usp%206586458&amp;summary=yes#jcite">458 patent</a>; and claim 2 of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> under the
Hatch-Waxman Act.<a HREF="#fn200" name="fnref_fn200">[fn2]</a><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2)(A); <i>Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 799</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. The Relevant `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 Patent</a> Claims
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found Appellants' ANDA products directly infringe Claim
15 of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a>, which depends on claim 5 and reads:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      5. A therapeutic package for dispensing to, or for use in
    dispensing to, a migraine patient, which comprises:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (a) one or more unit doses, each such unit dose comprising:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (i) a 5-HT agonist and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (ii) a long-acting, non-steroidal, anti-inflammatory drug
    (LA-NSAID);
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      wherein the respective amounts of said 5-HT agonist and said
    LA-NSAID in said unit dose are effective, upon concomitant
    administration to said patient of one or more of said unit doses, to
<span CLASS="page_no" data-cite="696 f 3d 1158" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1158" data-primary-citation="696 F.3d 1151">[*1158]</span> 
    reduce migraine relapse or produce longer lasting efficacy compared
    to the administration of said 5-HT agonist in the absence of said
    LA-NSAID or the administration of said LA-NSAID in the absence of
    said 5-HT agonist, and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (b) a finished pharmaceutical container therefor, said container
    containing said unit dose or unit doses, said container further
    containing or comprising labeling directing the use of said package
    in the treatment of migraine.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      . . . .
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      15. The improvement, method, or composition of claims 1, 2, 3, 4,
    5, 6, 7, or 8, wherein said 5-HT agonist is sumatriptan, said
    LA-NSAID is naproxen and the unit dosage form is an oral unit dosage
    form comprising sumatriptan in an amount greater than 15 mg, and
    naproxen <span CLASS="page_no" data-cite="2012 bl 251324 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> in an amount greater than 200 mg.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
`<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a> col.14 11.1-19; col.15 11.12-17.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  B. The Relevant `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3190C42I0J?jcsearch=usp%206586458&amp;summary=yes#jcite">458 Patent</a> Claims
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found Appellants' ANDA products directly infringe
claims 11, 12, and 24, which depend on claim 3, as well as claims 26, 27,
29, and 30, which specify sumatriptan <span CLASS="page_no" data-cite="104 uspq 2d 1974" data-cite-type="ReporterOfDecisions" data-cite-pageno="1974" data-primary-citation="104 U.S.P.Q.2d 1969">[**1974]</span> is the 5-HT agonist and naproxen is
the LA-NSAID used in various dosages. <i>Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 806</a>.
Representative claim 3 states:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      3. A pharmaceutical composition in unit dosage form, useful in
    treating a migraine headache patient, which comprises:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (a) a 5-HT agonist, wherein said 5-HT agonist is a triptan; and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      (b) a long-acting, non-steroidal, anti-inflammatory drug
    (LA-NSAID), wherein said LA-NSAID has a pharmacokinetic half-life of
    at least 4 hours and a duration of action of at least 6 hours;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      wherein the respective amounts of said 5-HT agonist and said
    LA-NSAID in said composition are effective, upon concomitant
    administration to said patient of one or more of said unit dosage
    forms of said composition, to produce longer lasting efficacy
    compared to the administration of said 5-HT agonist in the absence
    of said LA-NSAID or the administration of said LA-NSAID in the
    absence of said 5-HT agonist.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
`<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3190C42I0J?jcsearch=usp%206586458&amp;summary=yes#jcite">458 patent</a> col.12 11.29-45.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  C. The Relevant `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 Patent</a> Claims
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court held that under the doctrine of equivalents Par and
DRL's ANDA products infringe claim 2 of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a>, which is dependent
on claim 1, and reads:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      1. A multilayer pharmaceutical tablet comprising naproxen and a
    triptan and, wherein:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      a) substantially all of said triptan is in a first layer of said
    tablet and substantially all of said naproxen is in a second,
    separate layer; and
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      b)said first layer and said second layer are in a side by side
    arrangement such that the dissolution of said naproxen occurs
    independently of said triptan. 2. The tablet of claim 1, wherein
    said naproxen is in the form of naproxen sodium between 200 and 600
    mg.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
'<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> col. 18 11.30-39. The court construed the phrase "substantially
all of said triptan is in a first layer of said tablet and substantially all
of said naproxen is in a second, separate layer" as meaning "[a]t least 90%,
and preferably greater than 95%, of the total triptan present in the tablet
is included within one distinct layer and at least 90%, and preferably
greater than 95%, of the naproxen present in the tablet is included within a
second distinct layer." <i>Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 809</a>. The parties agreed that
the claim term "dissolution of said naproxen occurs independently of said
triptan" means "[d]issolution of naproxen . . . and triptan from the
multilayer tablet . . . occurs in the same
<span CLASS="page_no" data-cite="696 f 3d 1159" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1159" data-primary-citation="696 F.3d 1151">[*1159]</span> 
amount of time &plusmn; 10% as when the same amount of naproxen . . . and triptan
are given separately." Joint Appendix ("J.A.") 653.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  D. Procedural History
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Based on the ANDA filings, Pozen filed suit against Appellants for
infringement of the `<cite>499</cite>, `<cite>458</cite>, and `<cite>183 patents</cite> and asked for a permanent
injunction against Appellants from making, using, selling, offering to sell
or importing into the United States their ANDA products until the
patents-in-suit expire. <i>Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 799</a>. The lawsuit triggered a
30-month stay of FDA approval for Appellants' ANDAs. <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Following the claim <span CLASS="page_no" data-cite="2012 bl 251324 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> construction hearing, the district court conducted a
five-day bench trial regarding Pozen's infringement claims and Appellants'
noninfringement, invalidity, and unenforceability defenses and
counterclaims. The district court held, in part, that the patents were not
invalid because they were neither anticipated nor obvious in light of the
prior art, that Appellants' ANDA products infringed the `<cite>499</cite> and `<cite>458
patents</cite>, and that Par and DRL's ANDA products infringed the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a>. <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.</i>
Furthermore, the district court held that the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a> claims asserted
were not invalid due to lack of written description. <i></i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id. at 821-22</a>.
Accordingly, the district court enjoined Par, Alphapharm, and DRL from
making or selling their respective ANDA products. <i></i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id. at 826</a>. Par,
Alphapharm, and DRL filed a timely appeal.<a HREF="#fn300" name="fnref_fn300">[fn3]</a> We have jurisdiction over
the appeals pursuant to <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEIMUG003?jcsearch=28%20U.S.C.%20%201295(a)(1)&amp;summary=yes#jcite">28 U.S.C. &sect; 1295</a>(aXD.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span CLASS="page_no" data-cite="104 uspq 2d 1975" data-cite-type="ReporterOfDecisions" data-cite-pageno="1975" data-primary-citation="104 U.S.P.Q.2d 1969">[**1975]</span> DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. Standard of Review
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This court reviews judgments of the district court after a bench trial
"for errors of law and clearly erroneous findings of fact." <i>Zenon Envtl,</i>
<i>Inc. v. U.S. Filter Corp.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X17U76E003?jcsearch=506%20f%203d%201370&amp;summary=yes#jcite">506 F.3d 1370</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X17U76E003?jcsearch=506%20f%203d%201370&amp;summary=yes#jcite">1377</a> (Fed.Cir. 2007) (citations
and internal quotation marks omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellants challenge the validity of the `<cite>499</cite> and `<cite>458 patents</cite> in light of
four prior art references.<a HREF="#fn400" name="fnref_fn400">[fn4]</a> Appellants also challenge the validity of
the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> in light of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a> and prior art.<a HREF="#fn500" name="fnref_fn500">[fn5]</a> Appellants
ask this court to hold the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a> invalid for lack of written
description. Additionally, Appellants challenge the district court's
infringement determination as to the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a>. We address each argument
in turn.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  B. Invalidity
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  1. <i>The `A99 And `A58 Patents Are Not Obvious</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A party asserting invalidity must present clear and convincing evidence to
<span CLASS="page_no" data-cite="696 f 3d 1160" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1160" data-primary-citation="696 F.3d 1151">[*1160]</span> 
overcome a patent's presumption of validity. <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEJ050003?jcsearch=35%20usc%20282&amp;summary=yes#jcite">35 U.S.C. &sect; 282</a>; <i>Microsoft</i>
<i>Corp. v. i4i Ltd. P'ship</i>, <cite>___ U.S. ___</cite>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">131 S.Ct. 2238</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">2245</a>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1FI916003?jcsearch=180%20l%20ed%202d%20131&amp;summary=yes#jcite">180 L.Ed.2d 131</a> (2011). A patent claim is invalid as obvious "when `the
differences between the subject matter sought to be patented and the prior
art are such that the subject matter as a whole would have been obvious at
the time the invention was made to a person having ordinary skill in the
art. . . .'" <i>KSR Int'l Co. v. Teleflex Inc.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. 398</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">406</a>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XRIK7VQNB5G0?jcsearch=167%20l%20ed%202d%20705&amp;summary=yes#jcite">167 L.Ed.2d 705</a> (2007) (quoting <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103(a)&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>(a)). To
determine if a patent is obvious the district court looks to: (1) the scope
and content of the prior art; (2) differences between the prior art and the
claims; (3) the level of ordinary skill in the art; and (4) secondary
considerations such as commercial success and failure of others. <i>Graham v.</i>
<i>John Deere Co.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">383 U.S. 1</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">17</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X5C6EI?jcsearch=86%20supreme%20court%20684&amp;summary=yes#jcite">86 S.Ct. 684</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X5C6EI?jcsearch=15%20l%20ed%202d%20545&amp;summary=yes#jcite">15 L.Ed.2d 545</a> (1966).
"`Obviousness is a question of law, reviewed <i>de novo</i>, based upon underlying
factual questions which are reviewed for clear error following a bench
trial.'" <i>Aventis Pharma Deutsch-land GmbH v. Lupin, Ltd.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X17KB8A003?jcsearch=499%20f%203d%201293&amp;summary=yes#jcite">499 F.3d 1293</a>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X17KB8A003?jcsearch=499%20f%203d%201293&amp;summary=yes#jcite">1300</a> (Fed.Cir.2007) (quoting <i>Aha Corp. v. Mylan Labs., Inc.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X15KA98003?jcsearch=464%20f%203d%201286&amp;summary=yes#jcite">464 F.3d 1286</a>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X15KA98003?jcsearch=464%20f%203d%201286&amp;summary=yes#jcite">1289</a> (Fed.Cir.2006)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found that the prior art references did not invalidate
the `<cite>499</cite> and `<cite>458 patents</cite>. Specifically, the district court reasoned that
the references did not, separately or combined, "teach or suggest the
simultaneous administration of sumatriptan and naproxen. Nor . . . otherwise
disclose to one of ordinary skill in the art that the combination of
sumatriptan and naproxen produces a longer lasting efficacy reducing
<span CLASS="page_no" data-cite="2012 bl 251324 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> migraine relapse compared to the administration of naproxen or sumatriptan
alone." <i>Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 819</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As an initial matter, Par argues that the district court erred because it
failed to apply the term "concomitant administration" to include
simultaneous and sequential administration as it had been construed. If the
district court had applied the terms as construed, Par asserts, it would
have found the `<cite>499</cite> and `<cite>458 patents</cite> invalid because the prior art showed
concomitant administration.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_931140" href="#headnote_pq2-dec_931140">[1]</a> Within the context of the claim language the district court properly
applied its claim construction. In its obviousness analysis the district
court only referred directly to whether the references disclosed
"simultaneous administration," rather than using the broader term
"concomitant administration." <i>See Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 814-19</a>. The
district court construed the term "concomitantly administering" in the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499
patent</a> claims as:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Simultaneous administration; or administration of a second drug
    for migraine relief while a first drug for migraine relief is
    present in a therapeutically effective amount; or administration of
    a 5-HT agonist and NSAID such that the effective plasma levels of
    the NSAID will be present in a subject from about one hour to about
    12-24 <span CLASS="page_no" data-cite="104 uspq 2d 1976" data-cite-type="ReporterOfDecisions" data-cite-pageno="1976" data-primary-citation="104 U.S.P.Q.2d 1969">[**1976]</span> hours after the onset of migraine or onset of precursor
    symptoms of a migraine.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A.2554. The district court construed the term "concomitantly
administering" in the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3190C42I0J?jcsearch=usp%206586458&amp;summary=yes#jcite">458 patent</a> claims as "[g]iven in close enough
temporal proximity to allow their individual therapeutic effects to
overlap." J.A.2555. None of the parties contested the claim construction.
Before the bench trial the parties agreed that the claim terms "unit dose
form," "unit doses," and "unit dosage form(s)" in both the `<cite>499</cite> and `<cite>458
patents</cite> meant "single drug administration entity(ies)." Every asserted claim
in the `<cite>499</cite> and `<cite>458 patents</cite> contains the "unit dose" limitation. <i>See</i> `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499
patent</a> col. 14 ll.1-15; `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3190C42I0J?jcsearch=usp%206586458&amp;summary=yes#jcite">458 patent</a> col.12 ll.29-45. When
<span CLASS="page_no" data-cite="696 f 3d 1161" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1161" data-primary-citation="696 F.3d 1151">[*1161]</span> 
considering the claim language as a whole the term "unit dose" necessarily
limits concomitant administration to mean simultaneous administration
because a single drug administration entity cannot be administered in any
other fashion. <i>See Phillips v. AWH Corp.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X12HHT2003?jcsearch=415%20f%203d%201303&amp;summary=yes#jcite">415 F.3d 1303</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X12HHT2003?jcsearch=415%20f%203d%201303&amp;summary=yes#jcite">1314</a> (Fed.Cir.
2005) (en banc) ("[T]he context in which a term is used in the asserted
claim can be highly instructive."). Therefore, the district court properly
limited its analysis of the prior art to whether the references taught
simultaneous administration of naproxen and sumatriptan.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellants further argue that the `<cite>499</cite> and `<cite>458 patents</cite> should be invalid
as obvious in light of the prior art, asserting that references Parma,
Saadah, patient records from Henry Ford Hospital, or Catarci, alone or in
combination, teach a "concomitant administration" of sumatriptan and
naproxen to treat migraines. If the district court had followed the case law
and applied the claim construction, Appellants contend, it would have found
both the `<cite>499</cite> and `<cite>458 patents</cite> invalid. We consider each reference in turn.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  i. <i>The Parma Reference</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_931141" href="#headnote_pq2-dec_931141">[2]</a> The district court determined that the Parma reference does <span CLASS="page_no" data-cite="2012 bl 251324 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> not render the
`<cite>499</cite> and `<cite>458 patents</cite> obvious. <i>Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 815-16</a>. We agree.
Parma is an epidemiological survey assessing various migraine treatments
entitled, "The Treatment Of Migraine: A Study In General Medicine."<a HREF="#fn600" name="fnref_fn600">[fn6]</a> One
of the tables, labeled "Table VI. Combinations: 2 drugs," listed "FANS +
sumatriptan" (FANS is the Italian abbreviation for NSAIDs) among, fifteen
other drug combinations for the treatment of migraines. Another table,
labeled "Table VIII. `Unsatisfactory' treatments," lists percentages of
patients unsatisfied with various monotherapy treatments; included in that
list is "sumatriptan."
<span CLASS="page_no" data-cite="104 uspq 2d 1977" data-cite-type="ReporterOfDecisions" data-cite-pageno="1977" data-primary-citation="104 U.S.P.Q.2d 1969">[**1977]</span> <span CLASS="page_no" data-cite="696 f 3d 1162" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1162" data-primary-citation="696 F.3d 1151">[*1162]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Table VI. Combinations: 2 drugs (53 cases, type 1 and 2)</i>
</p></div>
<pre>
FANS + flunarizine               13
FANS + antiemetics               5
FANS + antidepressants           6
FANS + ergotamines               2
FANS + analgesics                2
FANS + sumatriptan               2
FANS + FANS                      1
FANS + other drugs               1
Ergotamines + benzodiazepine     1
Ergotamines + antidepressants    1
Ergotamines + other drugs        3
Sumatriptan + flunarizine        2
Sumatriptan + beta-blockers      1
Analgesic + analgesic            2
Various combinations             11
</pre>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A.242118.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b><i>Table VIII.</i></b> "<i>Unsatisfactory" treatments (migraine type 1 and 2)</i>
</p></div>
<pre>
                          <b>Monotherapy</b>  <b>Unsatisfactory treatments</b>  %
FANS                      118          44                         37.9
Sumatriptan               37           16                         43.2
Analgesics                89           49                         66.0
Ergotamine derivatives    18           14                         77.7
</pre>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A.242119.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellants' expert testified that Parma teaches simultaneous
administration of various drug combinations, and someone skilled in the art
would look at "Table VIII. `Unsatisfactory' treatments" and be motivated to
either administer another agent or administer a combination therapy. <i>Pozen</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 816</a>. The district court gave more weight to Pozen's expert
who testified that a person skilled in the art would have interpreted Parma
to disclose a sequential administration of various drug combinations. <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.</i> As
the tables reproduced above illustrate, Parma revealed the types of
treatments used and documented the number of unsatisfactory treatments
reported. Parma only specifies the unsatisfactory results of monotherapy
treatment in Table VIII; it does not indicate the relative successes of
various combination treatments listed in Table VI.<a HREF="#fn700" name="fnref_fn700">[fn7]</a> Furthermore, the
district <span CLASS="page_no" data-cite="104 uspq 2d 1978" data-cite-type="ReporterOfDecisions" data-cite-pageno="1978" data-primary-citation="104 U.S.P.Q.2d 1969">[**1978]</span> court found that Parma does hot disclose anything about the
combination of "FANS + sumatriptan" in particular reducing migraine re
<span CLASS="page_no" data-cite="696 f 3d 1163" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1163" data-primary-citation="696 F.3d 1151">[*1163]</span> 
lapse or producing longer lasting efficacy, nor does it disclose the dosage
of the combination treatment. <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.</i> Although the district court abused its
discretion by admitting the Tognoni declaration, <i>see supra</i> 1161 n. 6, it was
harmless error, there was not clear and convincing evidence that the `499
and `458 patents are obvious over the Parma reference.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  ii. <i>The Saadah Reference</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Saadah reference is a 1992 report entitled "Abortive Migraine Therapy
With Oral Naproxen Sodium Plus Metoclopramide Plus Ergotamine Tartrate With
Caffeine." It discloses the simultaneous delivery of several components:
ergotamine, which is a 5-HT agonist that at the time was a widely used
anti-migraine agent; metoclopramide and caffeine to reduce nausea and
improve "gastric emptying" which in turn leads to better absorption of
anti-migraine agents; and naproxen <span CLASS="page_no" data-cite="2012 bl 251324 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> for its pain and inflammation reduction
effects.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Par argues that another article, N.H. Raskin's "Acute and Prophylactic
Treatment of Migraine: Practical Approaches and Pharmacologic Rationale,"
("Raskin") shows sumatriptan has beneficial effects on nausea, and can be
used instead of ergotamine to treat migraines eliminating the need for a
concurrent antiemetic.<a HREF="#fn800" name="fnref_fn800">[fn8]</a> Therefore, Appellants contend, a person of
ordinary skill in the art would reasonably expect to successfully substitute
sumatriptan for ergotamine, both 5-HT agonists, in the treatment plan
disclosed by Saadah. Furthermore, Appellants contend that in substituting
sumatriptan for ergotamine, there would no longer be a need for antiemetics,
so metoclopramide and caffeine would be unnecessary. Accordingly, Appellants
assert, Saadah and Raskin together teach the simultaneous administration of
sumatriptan and naproxen, rendering the `499 and `458 patents obvious.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Pozen contends that a person of ordinary skill in the art motivated to
substitute sumatriptan for ergotamine would remove not only metoclopramide
and caffeine from the treatment plan but also naproxen because sumatriptan
was recognized to have analgesic and anti-inflammatory effects. Therefore,
Pozen argues, the formulation would result in sumatriptan monotherapy.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_931142" href="#headnote_pq2-dec_931142">[3]</a> The district court held that after reading Saadah, it is not obvious that
one could substitute sumatriptan for ergotamine and remove metoclopramide
and caffeine as unnecessary. <i>Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 817</a>. We agree. Saadah
disclosed each drug as having a specific purpose, and even though Raskin
teaches that antiemetics are unnecessary with sumatriptan, Raskin does not
provide the motivation to a skilled artisan to substitute one agent in place
of three. Nor does Saadah teach the remaining efficacy limitations, since it
gives no reason to assume that an entirely different combination of agents
would have the same success as the combination disclosed, nor does it
disclose the combination therapy has any added benefits over any of the
components given individually. <i>See Crocs, Inc. v. Int'l Trade Comm'n</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1CJGMG003?jcsearch=598%20f%203d%201294&amp;summary=yes#jcite">598 F.3d 1294</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1CJGMG003?jcsearch=598%20f%203d%201294&amp;summary=yes#jcite">1309</a> (Fed.Cir.2010) ("Even if the [patent at issue] were a
combination of known elements according to their established functions . . .
it yields more than predicable results" and thus is non-obvious.). The
district court did not clearly err in determining the scope of Saadah and
Raskin. Accordingly, as the district court held, the Saadah reference does
not
<span CLASS="page_no" data-cite="696 f 3d 1164" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1164" data-primary-citation="696 F.3d 1151">[*1164]</span> 
render the `<cite>499</cite> and `<cite>458 patents</cite> obvious to a person of ordinary skill in
the art.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  iii. <i>The Henry Ford Patient Records</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellants present two patient records from the Henry Ford Clinic in
Detroit, Michigan, showing doctors prescribed a daily dose of naproxen as a
prophylactic treatment, and sumatriptan for treating acute migraines.
Appellants argue that because the two agents would be working in the body at
the same time, even if taken separately, they are concomitantly
administered. Additionally, Appellants contend that a person of ordinary
skill in the art would expect a daily dose of naproxen <span CLASS="page_no" data-cite="2012 bl 251324 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> to have the same
effectiveness as a single dose of naproxen taken when needed because
concentration of the drug in the blood would be the same or higher.
Therefore, Appellants assert that when sumatriptan is taken in addition to a
daily dose of naproxen the combination of the <span CLASS="page_no" data-cite="104 uspq 2d 1979" data-cite-type="ReporterOfDecisions" data-cite-pageno="1979" data-primary-citation="104 U.S.P.Q.2d 1969">[**1979]</span> two drugs would have the same
effect as when the two drugs are given simultaneously.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_931143" href="#headnote_pq2-dec_931143">[4]</a> Dr. Ramadan, who treated the patients at the clinic, testified that he did
not recall ever prescribing or giving a patient sumatriptan and naproxen
simultaneously. Furthermore, the Henry Ford Records do not suggest that it
produced longer lasting efficacy or reduced migraine relapse. At least one
of the patients' prescriptions was soon altered to sumatriptan and an
antidepressant, suggesting the combination of sumatriptan and naproxen did
not work to relieve migraine symptoms. Accordingly, the district court did
not err in its determination of the scope of the teachings of the Henry Ford
Records; we hold that the patient records do not render the `<cite>499</cite> and `<cite>458
patents</cite> obvious.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  iv. <i>The Catarci Reference</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Catarci reference is a case report entitled "Ergotamine-Induced
Headache Can Be Sustained By Sumatriptan Daily Intake." Catarci describes a
single patient who developed ergotamine-induced headaches and subsequently
replaced ergotamine with daily administration of sumatriptan. Sumatriptan
effectively alleviated the patient's daily migraines but did not relieve her
constant mild headache. Catarci discloses that the patient was subsequently
taken off of sumatriptan and NSAIDs were "prescribed both on a daily basis
and when required." Catarci discloses that treating the patient's acute
migraine attacks with either NSAID or sumatriptan was not beneficial.
Instead the patient resumed taking a daily dose of sumatriptan in addition
to acupuncture and successfully treated acute migraines with additional
sumatriptan. Finally, Catarci concludes that acupuncture is beneficial "in
treating drug-induced daily headache." <i>Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 814</a> (internal
citations and quotations omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellants argue that Catarci shows a concomitant administration of
sumatriptan and naproxen was used to treat migraines as evidenced by the
patient's prescription of a daily NSAID as a prophylactic with sumatriptan
used as needed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_931144" href="#headnote_pq2-dec_931144">[5]</a> The district court did not clearly err in finding that Catarci does not
teach a combination of sumatriptan and naproxen provided migraine relief.
Rather, Catarci concludes that the only effective treatment for this patient
was sumatriptan and acupuncture. The district court determined that Catarci
discourages combining sumatriptan and naproxen to achieve the claimed
efficacy benefits, teaching away from the invention. <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.; see In re Gurley</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3MIHJ?jcsearch=27%20f%203d%20551&amp;summary=yes#jcite">27 F.3d 551</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3MIHJ?jcsearch=27%20f%203d%20551&amp;summary=yes#jcite">553</a> (Fed.Cir.1994) (A reference teaches away when "a person of
ordinary skill, upon reading the reference, would be discouraged from
following the
<span CLASS="page_no" data-cite="696 f 3d 1165" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1165" data-primary-citation="696 F.3d 1151">[*1165]</span> 
path set out in the reference, or would be led in a direction divergent from
the path that was taken by the applicant."); <i>see also Spectralytics, Inc. <span CLASS="page_no" data-cite="2012 bl 251324 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> v.</i>
<i>Cordis Corp.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1FIK08003?jcsearch=649%20f%203d%201336&amp;summary=yes#jcite">649 F.3d 1336</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1FIK08003?jcsearch=649%20f%203d%201336&amp;summary=yes#jcite">1343</a> (Fed.Cir.2011) (explaining that a jury
could find that prior art taught away from one solution because all prior
art taught a different solution). For the reasons given by the district
court, we agree that the Catarci reference does not render the `499 and `458
patents obvious.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  v. <i>Conclusion regarding prior art</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We agree with the district court that the prior art would not have
provided one of ordinary skill with motivation to combine sumatriptan and
naproxen in order to benefit from longer lasting efficacy as compared to
when either agent is taken alone. Appellants failed to rebut the presumption
of validity afforded issued patents by clear and convincing evidence.
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEJ050003?jcsearch=35%20usc%20282&amp;summary=yes#jcite">35 U.S.C. &sect; 282</a>; <i>Microsoft Corp.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">131 S.Ct. at 2245</a>; <i>see Pfizer, Inc. v.</i>
<i>Apotex, Inc.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X16HK1U003?jcsearch=480%20f%203d%201348&amp;summary=yes#jcite">480 F.3d 1348</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X16HK1U003?jcsearch=480%20f%203d%201348&amp;summary=yes#jcite">1361</a> (Fed.Cir.2007) ("[T]he burden falls on the
challenger of the patent to show by clear and convincing evidence that a
skilled artisan would have been motivated to combine the teachings of the
prior art references to achieve the claimed invention, and that the skilled
artisan would have had a reasonable expectation of success in doing-so.").
Therefore, the prior art references do not render the `<cite>499</cite> and `<cite>458 patents</cite>
obvious.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  2. <i>The `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 Patent</a> Is Not Invalid For Obviousness</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Par asserts, as it did before the district court, that the <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> is
obvious in light of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a>, combined with Bandelin and/or knowledge
of a person of ordinary skill in the art. Par argues the prior art taught
that naproxen has very low solubility in acidic environments like the
stomach, which would impede the dissolution of sumatriptan when the two are
administered together in a single unit dose. Therefore, a person of ordinary
skill in <span CLASS="page_no" data-cite="104 uspq 2d 1980" data-cite-type="ReporterOfDecisions" data-cite-pageno="1980" data-primary-citation="104 U.S.P.Q.2d 1969">[**1980]</span> the art would use a multilayer tablet, which was well known, to
resolve the physical incompatibility between sumatriptan and naproxen.
Additionally, Par contends that the district court failed to apply the
correct construction of "independent dissolution" by using the narrow
definition in its invalidity analysis when a plain and ordinary definition
of the term, which Par argues the district court used to find infringement,
would render the claim obvious.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_931145" href="#headnote_pq2-dec_931145">[6]</a> The district court explained that although the references submitted by Par
are different than what was before the PTO during prosecution, the content
of the references and the arguments made are the same.<a HREF="#fn900" name="fnref_fn900">[fn9]</a><i>Pozen</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 820</a>. The district court reasoned that, considering the
record and the arguments:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      It was not obvious to a person of ordinary skill in the art to
    formulate the naproxen sodium and sumatriptan into a bilayer
    configuration. While multilayer tablets were commonly used, Pozen's
    dosage forms of naproxen sodium and sumatriptan were not obvious.
    Nor do the references render obvious the specific tablet
    architecture as Pozen argued to the PTO and claimed in the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183
    patent</a>. Accordingly, Defendants failed to rebut the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a>'s
    presumption of validity by clear and convincing evidence.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i></i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id. at 821</a> (citation omitted). Par concedes that using a "narrow"
interpretation of the
<span CLASS="page_no" data-cite="696 f 3d 1166" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1166" data-primary-citation="696 F.3d 1151">[*1166]</span> 
term "independent dissolution" does not invalidate the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a>. <span CLASS="page_no" data-cite="2012 bl 251324 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> We
agree.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Par contends that the district court improperly used a different
construction of "independent dissolution" in its infringement analysis and
invalidity analysis. Par argues that the district court's infringement
analysis was conducted under the plain and ordinary meaning of the
independent dissolution limitation, whereas the validity analysis uses a
narrower definition. <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.</i> However, Par fails to explain the "plain and
ordinary meaning" of independent dissolution and identify how it differs
from the "narrow" meaning. In its infringement analysis the district court
construed "independent dissolution" as that term is defined in the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183
patent</a> and does not appear to define that term in its invalidity analysis
any differently.<a HREF="#fn1000" name="fnref_fn1000">[fn10]</a> Regardless of what definition is applied, Appellants
failed to rebut the presumption of validity afforded issued patents by clear
and convincing evidence. The district court correctly held that the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183
patent</a> was not obvious.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  3. <i>The `k99 Patent Is Not Invalid For Lack Of Written Description</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellants argue that the district court erred in finding claim 15 of the
`<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a> not invalid because the limitations "therapeutic package,"
"finished pharmaceutical container," and "said container further containing
or comprising labeling directing the use of said package in the treatment of
migraine" lack adequate written description in the specification. Appellants
assert that the terms were added during prosecution and that, although the
exact term need not be recited, "the specification must contain an
equivalent description of the claimed subject matter," and there was no
description of these limitations. <i>Lockwood v. Am. Airlines, Inc.</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3AOVM?jcsearch=107%20f%203d%201565&amp;summary=yes#jcite">107 F.3d 1565</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3AOVM?jcsearch=107%20f%203d%201565&amp;summary=yes#jcite">1572</a> (Fed.Cir.1997).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEIVVO003?jcsearch=35%20U.S.C.%20%20112&amp;summary=yes#jcite">Section 112</a>, paragraph 1 of the Patent Act, requires that the
specification contain a written description of the invention.
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEIVVO003?jcsearch=35%20usc%20112&amp;summary=yes#jcite">35 U.S.C. &sect; 112</a>, &para; 1. The purpose of the written description requirement is
to ensure adequate disclosure of the invention. <i>Ariad Pharms., Inc. v. Eli</i>
<i>Lilly &amp; Co.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1CS7VQ003?jcsearch=598%20f%203d%201336&amp;summary=yes#jcite">598 F.3d 1336</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1CS7VQ003?jcsearch=598%20f%203d%201336&amp;summary=yes#jcite">1351</a> (Fed.Cir.2010) (en banc). A specification
adequately describes an invention when it "reasonably conveys to those
skilled in the art that the inventor had possession of the claimed subject
matter as of the filing date." <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1CS7VQ003?jcsearch=598%20F.3d%201336&amp;summary=yes#jcite">Id</a>.</i> Following a bench trial, we review
compliance with the written description requirement, a question of fact, for
clear error. <i>Tech. Licensing Corp. v. Videotek, Inc.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X19PAK6003?jcsearch=545%20f%203d%201316&amp;summary=yes#jcite">545 F.3d 1316</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X19PAK6003?jcsearch=545%20f%203d%201316&amp;summary=yes#jcite">1332</a>
(Fed.Cir.2008).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_931146" href="#headnote_pq2-dec_931146">[7]</a> The `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a> discloses several dosage forms, including an oral unit
dosage, to teach treating migraines by concomitantly administering
therapeutic amounts of sumatriptan and naproxen. `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a> col.3 ll.22-50,
col.4 ll.1-4, col. 12 ll.54-55, col.15 ll.12-17. The district court found
that "[b]ased on these disclosures, persons of skill in the art would know
<span CLASS="page_no" data-cite="104 uspq 2d 1981" data-cite-type="ReporterOfDecisions" data-cite-pageno="1981" data-primary-citation="104 U.S.P.Q.2d 1969">[**1981]</span> these pharmaceutical dosages are administered to a patient in containers or
packages with labeling and inserts with dosage instructions." <i>Pozen</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 821</a>. Specifically, the district court reasoned that
"[d]ispensing pharmaceutical products in containers or packages is not a new
or unpredictable concept. A person of ordinary skill in the art <span CLASS="page_no" data-cite="2012 bl 251324 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> would know
that medications are not simply handed out to patients. Rather,
pharmaceutical products, like the claimed tablets, are routinely
administered in containers or packages." <i></i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id. at 822</a>. Moreover, the FDA
requires container labeling and information for prescription pharmaceutical
products. <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.</i>
<span CLASS="page_no" data-cite="696 f 3d 1167" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1167" data-primary-citation="696 F.3d 1151">[*1167]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a> specification meets the written description requirement
because the specification describes the invention in such a way that it is
understandable to a person of ordinary skill in the art. <i>See Ariad</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1CS7VQ003?jcsearch=598%20f%203d%201336&amp;summary=yes#jcite">598 F.3d at 1351</a>. As this court has explained, "[i]n order to satisfy the
written description requirement, the disclosure as originally filed does not
have to provide <i>in haec verba</i> support for the claimed subject matter at
issue Nonetheless, the disclosure . . . must convey with reasonable clarity
to those skilled in the art that . . . [the inventor] was in possession of
the invention." <i>Purdue Pharma L.P. v. Faulding Inc.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3IV8H?jcsearch=230%20f%203d%201320&amp;summary=yes#jcite">230 F.3d 1320</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3IV8H?jcsearch=230%20f%203d%201320&amp;summary=yes#jcite">1323</a>
(Fed.Cir.2000); <i>see LizardTech, Inc. v. Earth Resource Mapping, Inc.</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X13A770003?jcsearch=424%20f%203d%201336&amp;summary=yes#jcite">424 F.3d 1336</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X13A770003?jcsearch=424%20f%203d%201336&amp;summary=yes#jcite">1345</a> (Fed.Cir.2005) ("[T]he patent specification is written
for a person of skill in the art, and such a person comes to the patent with
the knowledge of what has come before Placed in that context, it is
unnecessary to spell out every detail of the invention in the specification;
only enough must be included to convince a person of skill in the art that
the inventor possessed the invention and to enable such a person to make and
use the invention without undue experimentation."). The district court
reasonably found that one skilled in the art would understand the meaning of
"therapeutic package" and "finished pharmaceutical container." There is no
clear error in the district court's finding that there is adequate written
description to support the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a> validity.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  C. The District Court Did Not Err In Finding That Appellants' AND A
Products Infringe The `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 Patent</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  There are two types of infringement: literal infringement, which is not at
issue here, and infringement under the doctrine of equivalents.<a HREF="#fn1100" name="fnref_fn1100">[fn11]</a> "The
doctrine of equivalents allows the patentee to claim those insubstantial
alterations that were not captured in drafting the original patent claim but
which could be created through trivial changes." <i>Festo Corp. v. Shoketsu</i>
<i>Kinzoku Kogyo Kabushiki Co.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XG4UTV?jcsearch=535%20us%20722&amp;summary=yes#jcite">535 U.S. 722</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XG4UTV?jcsearch=535%20us%20722&amp;summary=yes#jcite">733</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XG4UTV?jcsearch=122%20supreme%20court%201831&amp;summary=yes#jcite">122 S.Ct. 1831</a>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XG4UTV?jcsearch=152%20l%20ed%202d%20944&amp;summary=yes#jcite">152 L.Ed.2d 944</a> (2002). "However, the `all limitations rule' restricts the
doctrine of equivalents by preventing its application when doing so would
vitiate a claim limitation." <i>Carnegie Mellon Univ. v. Hoffmann-La Roche</i>
<i>Inc.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X19H3Q0003?jcsearch=541%20f%203d%201115&amp;summary=yes#jcite">541 F.3d 1115</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X19H3Q0003?jcsearch=541%20f%203d%201115&amp;summary=yes#jcite">1129</a> (Fed.Cir.2008) (quoting <i>Warner-Jenkinson Co. v.</i>
<i>Hilton Davis Chem. Co.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X5CCSV?jcsearch=520%20us%2017&amp;summary=yes#jcite">520 U.S. 17</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X5CCSV?jcsearch=520%20us%2017&amp;summary=yes#jcite">29</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X5CCSV?jcsearch=117%20supreme%20court%201040&amp;summary=yes#jcite">117 S.Ct. 1040</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X5CCSV?jcsearch=137%20l%20ed%202d%20146&amp;summary=yes#jcite">137 L.Ed.2d 146</a>
(1997)). Equivalence "`is not an absolute to be considered in a vacuum.'"
<i>Warner-Jenkinson</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X5CCSV?jcsearch=520%20us%2017&amp;summary=yes#jcite">520 U.S. at 24-25</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X5CCSV?jcsearch=117%20supreme%20court%201040&amp;summary=yes#jcite">117 S.Ct. 1040</a> (quoting <i>Graver Tank &amp;</i>
<i>Mfg. Co. v. Linde Air Prods. Co.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X5C1QF?jcsearch=339%20us%20605&amp;summary=yes#jcite">339 U.S. 605</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X5C1QF?jcsearch=339%20us%20605&amp;summary=yes#jcite">609</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X5C1QF?jcsearch=70%20supreme%20court%20854&amp;summary=yes#jcite">70 S.Ct. 854</a>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X5C1QF?jcsearch=94%20l%20ed%201097&amp;summary=yes#jcite">94 L.Ed. 1097</a> (1950)). The essential inquiry is whether "the accused product
or process contain[s] elements identical or equivalent to each claimed
element of the patented invention." <i>Id.</i> at 40, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X5CCSV?jcsearch=117%20supreme%20court%201040&amp;summary=yes#jcite">117 S.Ct. 1040</a>. One way of
proving infringement under the doctrine of equivalents "is by showing on a
limitation by limitation basis that the accused product performs
substantially the same function in substantially the same way with
substantially the same result <span CLASS="page_no" data-cite="2012 bl 251324 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[***12]</span> as each claim limitation of the patented
product." <i>Crown Packaging Tech., Inc. v. Rexam Beverage Can Co.</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1AP0OK003?jcsearch=559%20f%203d%201308&amp;summary=yes#jcite">559 F.3d 1308</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1AP0OK003?jcsearch=559%20f%203d%201308&amp;summary=yes#jcite">1312</a> (Fed.Cir.2009). We review the district court's
infringement determinations under the doctrine of equivalents for clear
error. <i>Conoco, Inc. v. Energy &amp; Env't Int'l</i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X15HQJ4003?jcsearch=460%20f%203d%201349&amp;summary=yes#jcite">460 F.3d 1349</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X15HQJ4003?jcsearch=460%20f%203d%201349&amp;summary=yes#jcite">1357</a>
(Fed.Cir.2006).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span CLASS="page_no" data-cite="696 f 3d 1168" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1168" data-primary-citation="696 F.3d 1151">[*1168]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found that Par and DRL's ANDA products infringed claim
2 of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> under the doctrine of equivalents. <i>Pozen</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 812</a>. On appeal the Appellants challenge the district
court's findings that the Appellants' ANDA products meet the "independent
dissolution" limitation and the "substantially all" limitation. We address
each in turn.
<span CLASS="page_no" data-cite="104 uspq 2d 1982" data-cite-type="ReporterOfDecisions" data-cite-pageno="1982" data-primary-citation="104 U.S.P.Q.2d 1969">[**1982]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  1. <i>The "Independent Dissolution" Limitation</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The parties agreed that the limitation "dissolution of said naproxen
occurs independently of said triptan" as recited in claim 1 of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183
patent</a> means "[d]issolution of naproxen . . . and triptan from the
multilayer tablet . . . occurs in the same amount of time &plusmn; 10% as when the
same amount of naproxen . . . and triptan are given separately" as it was
described in the patent specification. J.A.653; `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> col.2 ll.48-54.
Based on the evidence presented the district court found "Pozen has shown by
a preponderance of the evidence the accused ANDA products achieve
independent dissolution." <i>Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 811-12</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Relying upon Par's FDA filings and expert testimony presented at trial,
the district court found that Par's ANDA product performs the same function
in the same way to achieve the same results and there-fore satisfies the
independent dissolution limitation under the doctrine of equivalents. <i>Pozen</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 810</a>. Pozen's expert noted that Par's ANDA product was
specifically formulated to achieve complete and independent dissolution.
J.A. 6029. Moreover, in its ANDA, Par represented to the FDA that the
sumatriptan and naproxen in its ANDA product dissolves completely and
independently from each other. J.A. 157587; J.A. 157602; J.A. 158055.<a HREF="#fn1200" name="fnref_fn1200">[fn12]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court similarly found that DRL's ANDA product achieves
independent dissolution "by the way it formulates and manufactures the
tablets." <i>Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 810</a>. Relying upon the parties' ANDA
disclosures and expert testimony, the district court found that
"substantially all the triptan is segregated and separated into the
equivalent of a first distinct layer, in an equivalent side-by-side
arrangement, and this achieves the result of independent dissolution." <i></i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id.
at 811</a>. Moreover, the district court found "DRL's testing of its ANDA
product confirms its independent dissolution." <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.</i><a HREF="#fn1300" name="fnref_fn1300">[fn13]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Notwithstanding the evidence presented at trial, Appellants argue that
Pozen did not prove independent dissolution because there is no evidence on
the record that the comparison required by the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> was ever
undertaken. Specifically, Appellants contend that there is no proof that the
independent dissolution achieved by the ANDA products was compared to
dissolution rates of the same amount of naproxen or sumatriptan alone.
Appellants
<span CLASS="page_no" data-cite="696 f 3d 1169" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1169" data-primary-citation="696 F.3d 1151">[*1169]</span> 
thus ask this court to find the district court erred by not requiring any
proof that the active agents in their ANDA products achieved dissolution in
<span CLASS="page_no" data-cite="2012 bl 251324 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[***13]</span> about the same time (&plusmn; 10%) it would take for either of the active agents to
achieve dissolution when taken alone.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_931147" href="#headnote_pq2-dec_931147">[8]</a> The district court did not clearly err in finding infringement under the
doctrine of equivalents because the record contains sufficient evidence that
the independent dissolution requirement of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> was met. In
assessing equivalents, the court considers whether "the accused product[s]
perform[] substantially the same function in substantially the same way with
substantially the same result as each claim limitation of the patented
product." <i>Crown Packaging Tech.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1AP0OK003?jcsearch=559%20f%203d%201308&amp;summary=yes#jcite">559 F.3d at 1312</a>. Although there is no
direct evidence comparing the rate of dissolution of the ANDA products to
that of the agents individually, no such actual comparison was necessary.
Under the doctrine of equivalents analysis Pozen need only show that the
ANDA products performed the same function in the same way to achieve the
same result as the claimed elements of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a>. Par and DRL provided
expert testimony to show that the sumatriptan dissolves completely and
independently from the naproxen and that the naproxen dissolves completely
and independently from the sumatriptan in their ANDA products. Also, there
is probative evidence from Par's ANDA and comparison of DRL's ANDA products
dissolution profile showing that their sumatriptan and naproxen dissolve
<span CLASS="page_no" data-cite="104 uspq 2d 1983" data-cite-type="ReporterOfDecisions" data-cite-pageno="1983" data-primary-citation="104 U.S.P.Q.2d 1969">[**1983]</span> completely and independently from another. As a result, Appellants offer no
basis for setting aside the district court's finding. Indeed, there is
sufficient evidence showing that logically if the agents dissolve in the
same way they would if the other agent was not present, their dissolution
takes the same amount of time it would taken when given separately. Thus,
the district court did not clearly err in relying on Pozen's expert
testimony and concluding that Appellants' ANDA products meet the
"independent dissolution" limitation as recited in claim 1 of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183
patent</a> under the doctrine of equivalents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  2. <i>Infringement Of The "Substantially All" Limitation</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Claim 1 of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> requires "substantially all of said triptan is
in the first layer of said tablet and substantially all of said naproxen is
in a second, separate layer." `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> col. 18 ll.30-39. The district
court construed this phrase as "at least 90%, and preferably greater than
95%, of the total triptan present in the tablet is included within one
distinct layer and at least 90%, and preferably greater than 95%, of the
naproxen present in the tablet is included within a second distinct layer."
<i>Pozen Inc. v. Par Pharm., Inc.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1Q6LC58K082?jcsearch=719%20f%20supp%202d%20718&amp;summary=yes#jcite">719 F.Supp.2d 718</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1Q6LC58K082?jcsearch=719%20f%20supp%202d%20718&amp;summary=yes#jcite">734</a> (E.D.Tex.2010). It is
undisputed that the first layer of Par's ANDA tablet "contains 100% of the
tablet's sumatriptan, along with 15% of the tablet's naproxen, with the
remaining 85% of the naproxen in the second layer. DRL's ANDA tablet has
100% of the tablet's naproxen and 15% of the tablet's sumatriptan in the
first layer, with the remaining 85% of the sumatriptan in the second layer."
<i>Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 809</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  i. <i>The doctrine of equivalents can apply to the "substantially all"</i>
<i>limitation</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court recognized that the claim <span CLASS="page_no" data-cite="2012 bl 251324 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[***14]</span> construction of the term
"substantially all" provided specific percentages but stated that "absent
more limiting language in the intrinsic record" the doctrine of equivalents
can be applied to find infringement where the accused value is
insubstantially different from the claimed value. <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.</i> (quoting <i>Adams</i>
<i>Respiratory Therapeutics</i>,
<span CLASS="page_no" data-cite="696 f 3d 1170" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1170" data-primary-citation="696 F.3d 1151">[*1170]</span> 
<i>Inc. v. Perrigo Co.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1DTP52003?jcsearch=616%20f%203d%201283&amp;summary=yes#jcite">616 F.3d 1283</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1DTP52003?jcsearch=616%20f%203d%201283&amp;summary=yes#jcite">1292</a> (Fed.Cir.2010)); <i>see also U.S.</i>
<i>Philips Corp. v. Iwasaki Elec. Co.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X17VI9S003?jcsearch=505%20f%203d%201371&amp;summary=yes#jcite">505 F.3d 1371</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X17VI9S003?jcsearch=505%20f%203d%201371&amp;summary=yes#jcite">1378</a> (Fed.Cir.2007)
(holding that despite a claimed concentration range the doctrine of
equivalents can still be applied).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Par argues that the district court improperly treated the claim term
"substantially all" as a precise quantity entitled to the doctrine of
equivalents when it is really a "fuzzy" quantitative limitation not entitled
to equivalents. Par asserts that the word "substantially" was used to
capture values lower than 100%, indeed the district court construed the term
to include any amount as low as 90%, and Par contends Pozen should not reach
below 90% "to encompass equivalents of equivalents." <i>Cohesive Techs., Inc.</i>
<i>v. Waters Corp.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X19OH88003?jcsearch=543%20f%203d%201351&amp;summary=yes#jcite">543 F.3d 1351</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X19OH88003?jcsearch=543%20f%203d%201351&amp;summary=yes#jcite">1372</a> (Fed.Cir.2008).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  DRL argues that the district court erred in granting Pozen a range of
equivalency for the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> beyond the scope of equivalency determined
through claim construction. DRL asserts that in the cases the district court
cites the degree to which the accused product fell outside the specifically
claimed range was miniscule in comparison to the amount their ANDA product
falls outside of the claimed range.<a HREF="#fn1400" name="fnref_fn1400">[fn14]</a> Here, DRL contends, sumatriptan
only makes up 85% of one layer; 5% less than the minimum 90% set forth in
the construction of the term "substantially all."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Indeed, this court has stated that where "a patentee has brought what
would otherwise be equivalents of a limitation into the literal scope of the
claim, the doctrine of equivalents is unavailable to further broaden the
scope of the claim." <i>Cohesive Techs.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X19OH88003?jcsearch=543%20f%203d%201351&amp;summary=yes#jcite">543 F.3d at 1372</a>. "[A]ll claim
limitations are not entitled to an equal scope of equivalents. Whether the
result of the All Limitations Rule, prosecution history estoppel, or the
inherent narrowness of the claim language, many limitations warrant little,
if any, range of equivalents." <i>Moore U.S.A. Inc. v. Standard Register Co.</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3FMA8?jcsearch=229%20f%203d%201091&amp;summary=yes#jcite">229 F.3d 1091</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3FMA8?jcsearch=229%20f%203d%201091&amp;summary=yes#jcite">1106</a> (Fed.Cir.2000) (internal citations omitted).
<span CLASS="page_no" data-cite="104 uspq 2d 1984" data-cite-type="ReporterOfDecisions" data-cite-pageno="1984" data-primary-citation="104 U.S.P.Q.2d 1969">[**1984]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_931148" href="#headnote_pq2-dec_931148">[9]</a> However, although the claim language itself is a qualitative measure, the
claim construction pulls directly from the specification to give the term
"substantially all" a quantitative definition, specifically, "at least 90%,
and preferably greater than 95%," `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> col.2 ll.62-65, and this court
has previously concluded that the doctrine of equivalents is not foreclosed
with respect to claimed ranges, <i>see Adams Respiratory</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1DTP52003?jcsearch=616%20f%203d%201283&amp;summary=yes#jcite">616 F.3d at 1291-92</a>.
In <i>Kemin Foods</i>, the court construed "substantially free from other
carotenoids" to mean "significantly less than 10% of other carotenoids"
based, in part, on the specification stating that "[g]enerally, the
concentration of other carotenoids in the starting material should be 10% or
less." <i>Kemin Foods, L.C. v. Pigmentos Vegetates Del Centro S.A. de C.V.</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X15MG7Q003?jcsearch=464%20f%203d%201339&amp;summary=yes#jcite">464 F.3d 1339</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X15MG7Q003?jcsearch=464%20f%203d%201339&amp;summary=yes#jcite">1349</a> (Fed.Cir. 2006). The court determined that because Kemin
did not argue <span CLASS="page_no" data-cite="2012 bl 251324 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[***15]</span> that "significantly less than 10%" has a precise upper limit a
reasonable person could determine that a concentration of 6.14% &mdash; 9.86% does
not in-fringe under the doctrine of equivalents. <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X15MG7Q003?jcsearch=464%20F.3d%201339&amp;summary=yes#jcite">Id</a>.</i> Similarly, in this
case, Pozen never stated that "at least 90%, and preferably greater than
95%" should be an absolute floor. Under the doctrine of equivalents a
<span CLASS="page_no" data-cite="696 f 3d 1171" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1171" data-primary-citation="696 F.3d 1151">[*1171]</span> 
tablet layer with 85% of the agent can be fairly characterized as an
insubstantial change from a tablet layer with 90% of the agent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  ii. <i>Appellants' ANDA products infringe the "substantially all" limitation</i>
<i>under the doctrine of equivalents</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Turning now to the district court's analysis of infringement of the
"substantially all" limitation, we review the district court's findings of
infringement under the doctrine of equivalents for clear error. <i>Conoco</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X15HQJ4003?jcsearch=460%20f%203d%201349&amp;summary=yes#jcite">460 F.3d at 1357</a>. The district court stated that the multilayer tablet
claimed in the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> requires "substantially all of the naproxen and
triptan [to be] segregated and separated for the purpose of independent
dissolution." <i>Pozen</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 810</a>. The parties' experts agreed that
the function was to have "separate, distinct layers of sumatriptan and
naproxen. The way in which this function is achieved is by formulating the
sumatriptan and naproxen in different manners to create physical barriers.
The result is that substantially naproxen is separated from the
[sumatriptan], thereby providing independent dissolution." <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found that Par's ANDA product performs essentially the
same function, by segregating the naproxen and sumatriptan into two layers.
<i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.</i> This is achieved by formulating them differently, specifically, by using
a polymer binder to form 15% of the naproxen into granules which are added
to the sumatriptan layer. <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.</i> The result is that one layer has 100% of the
sumatriptan with 15% of the naproxen, and another layer has the remaining
85% of the naproxen, substantially all separated and segregated into two
layers. <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.</i> Therefore, the district court determined, Par's ANDA product
performs the same function, in the same way, and achieves the same result,
and satisfies all of the limitations of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> under the doctrine
of equivalents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court also found that DRL's ANDA product performs the same
function of achieving separate, distinct layers by segregating the triptan
and naproxen. <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.</i> This is achieved by granulating 15% of the sumatriptan
with a polymer binder and then spraying it on the naproxen which has been
granulated with a polymer binder as well; the remaining 85% of the
sumatriptan forms the other layer. <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id</a>.</i> "Thus, substantially all the triptan
is segregated and separated into the equivalent of a first distinct layer,
in an equivalent side-by-side arrangement, and this achieves the result of
independent dissolution." <i></i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">Id. at 811</a>. Therefore, the district court
determined, DRL's ANDA product performs the same function, in the same way,
and achieves the same result, and satisfies all of the limitations of the
`<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> under the doctrine of equivalents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellants argue that their ANDA products do not achieve <span CLASS="page_no" data-cite="2012 bl 251324 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[***16]</span> separate distinct
layers because one of the layers has both agents. However, their products
contain a bilayer tablet, with 100% of one agent in one layer, and 85% of
the other agent in the other layer. We determine, as the district court did,
that this structure is insubstantially different from a bilayer tablet with
90% of the total therapeutic agent present in the tablet included in a
single layer.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellants contend that their products are admixtures which Pozen
specifically disclaimed during the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> prosecution. DRL argues that
the district court improperly limited Pozen's disclaimer to admixtures that
achieve independent dissolution, when it really <span CLASS="page_no" data-cite="104 uspq 2d 1985" data-cite-type="ReporterOfDecisions" data-cite-pageno="1985" data-primary-citation="104 U.S.P.Q.2d 1969">[**1985]</span> disclaimed admixtures in
general. We agree that Pozen did
<span CLASS="page_no" data-cite="696 f 3d 1172" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1172" data-primary-citation="696 F.3d 1151">[*1172]</span> 
in fact disclaim admixtures when it stated before the PTO:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      The present claims require that naproxen and [sumatriptan] be in a
    tablet in which they are segregated from one another in a "side by
    side arrangement" and in which their dissolution occurs
    independently of one another. The claims are limited to one very
    specific tablet architecture. Among the dosage forms falling outside
    the claims are: admixtures; any dosage forms other than tablets;
    tablets in which one drug is in a core and surrounded by a layer or
    coating containing the second drug; and tablets containing multiple
    drug release pellets or microparticles.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A.240667. However, the Appellants' ANDA products are not admixtures, i.e.
substances with blended or mixed ingredients, because substantially all of
the agents are separated and segregated into two distinct layers, as
explained above.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Based on the evidence above, the district court did not clearly err in
finding that Par's ANDA products and DRL's ANDA products met the
"substantially all" limitation of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> under the doctrine of
equivalents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  CONCLUSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Appellants failed to rebut the presumption of validity of issued patents,
thus, we affirm the district court's holding that the `<cite>499</cite>, `<cite>458</cite>, and `<cite>183
patents</cite> are not invalid. Additionally the Appellants provided no basis for
unsettling the district court's finding on infringement. Accordingly, we
affirm the district court's injunction enjoining Appellants from making,
using, importing, selling or offering to sell their ANDA products, or
inducing others to do so, until the expiration of the `<cite>499</cite>, `<cite>458</cite>, and `<cite>183
patents</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>AFFIRMED</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> After the district court issued its final claim construction order,
Pozen stipulated to a judgment of noninfringement of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> in
favor of Alphapharm. Therefore, Alphapharm's interest in this appeal is
limited to the validity of the `<cite>499</cite> and `<cite>458</cite> patents. Pozen also sued Teva
Pharmaceuticals USA, Inc. ("Teva") for patent infringement on the basis of
Teva's ANDA, but the parties settled before trial. <i>Pozen Inc. v. Par Pharm.,</i>
<i>Inc.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20f%20supp%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d 789</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20f%20supp%202d%20789&amp;summary=yes#jcite">796</a> n. 1 (E.D.Tex.2011).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> It is "an act of infringement to submit . . . an application" for
approval from the FDA to manufacture "a drug claimed in a patent."
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2)(A). <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">Section 271(e)(2)</a>(A) provides that an ANDA
constitutes an artificial act of infringement for which the applicant may be
liable. <i>Warner-Lambert</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X17O53QNB5G0?jcsearch=316%20F.3d%201348&amp;summary=yes#jcite">316 F.3d at 1365</a>. It "creates case-or-controversy
jurisdiction to enable the resolution of an infringement dispute before the
ANDA applicant has actually made or marketed the proposed product." <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X17O53QNB5G0?jcsearch=316%20F.3d%201348&amp;summary=yes#jcite">Id</a>.; see</i>
<i>Glaxo, Inc. v. Novopharm, Ltd.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X31Q33?jcsearch=110%20f%203d%201562&amp;summary=yes#jcite">110 F.3d 1562</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X31Q33?jcsearch=110%20f%203d%201562&amp;summary=yes#jcite">1569</a> (Fed.Cir.1997). The
determination under <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271&amp;summary=yes#jcite">&sect; 271</a> is the same as any other infringement suit to
inquire whether a product would infringe a patent if the ANDA product was on
the market. <i>Warner-Lambert</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X17O53QNB5G0?jcsearch=316%20F.3d%201348&amp;summary=yes#jcite">316 F.3d at 1365</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> Par and Alphapharm filed a joint brief, Brief for
Defendants-Appellants Par Pharmaceutical, Inc. and Alphapharm Pty Ltd.
("Par's Br.") and DRL submitted a separate brief, Brief for
Defendant-Appellant Dr. Reddy's Laboratories, Inc. ("DRL's Br."), adopting
in accordance with Fed. R.App. P. <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X135J86003?jcsearch=Fed.%20R.%20App.%20P.%2028(i)&amp;summary=yes#jcite">28</a>(i) Par and Alphapharm's arguments with
regard to invalidity of the `<cite>499</cite>, `<cite>458</cite>, and `<cite>183 patents</cite> over the prior art,
DRL's Br. at 1.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> The following references will be discussed below: Parma, E., et al.,
<i>The Treatment of Migraine: A Study in General Medicine</i>, 11 Ricerca &amp;
Practica 1995, at 64 ("Parma"); Saadah, H., <i>Abortive Migraine Therapy With</i>
<i>Oral Naproxen Sodium Plus Metoclopramide Plus Ergotamine Tartrate With</i>
<i>Caffeine</i>, 32 Headache 1992, at 95 ("Saadah"); Raskin, N., <i>Acute and</i>
<i>Prophylactic Treatment of Migraine: Practical Approaches and Pharmacologic</i>
<i>Rationale</i>, 43 Neurology, June 1993, at 839 ("Raskin"); Henry Ford Hospital,
Patient Records; Catarci et al., <i>Ergotamine-Induced Headache Can Be</i>
<i>Sustained By Sumatriptan Daily Intake</i>, 14 Cephalalgia 1994, at 374
("Catarci").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> Bandelin, R., <i>Compressed Tablets by Wet Granulation</i>, 179 Herbert
Lieberman et al. eds. (2d ed. 1989) ("Bandelin").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> At trial, Pozen presented, and the district court allowed into
evidence, a declaration from one of the coauthors of the Parma reference,
referred to as the "Tognoni declaration," which stated:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
While my article speaks of [combination therapy] of many pairs of drugs,
including NSAIDs and sumatriptan, this is not meant as a reference to
administering those two drugs at the same time. . . . it refers to the
common practice of that time of migraine patients taking drugs separately in
sequence, with a required gap in time between administrations of the drugs
to determine the efficacy of the first drug before trying additional drugs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A.158512.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
DRL argues that the declaration is inadmissible as hearsay and irrelevant,
and in admitting it the district court abused its discretion. DRL's Br. at
52. Pozen argues that the declaration is admissible under the residual
hearsay rule, Fed. R. of Evid. <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X135KN6003?jcsearch=Fed.%20R.%20of%20Evid.%20807&amp;summary=yes#jcite">807</a>. <i>See</i> Pozen's Br. at 30. We review
evidentiary determinations under the law of the regional circuit. <i>Lexion</i>
<i>Med. v. Northgate Techs., Inc.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1FBOU8003?jcsearch=641%20f%203d%201352&amp;summary=yes#jcite">641 F.3d 1352</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1FBOU8003?jcsearch=641%20f%203d%201352&amp;summary=yes#jcite">1358</a> (Fed.Cir.2011). The
Fifth Circuit reviews decisions to admit or exclude evidence for abuse of
discretion. <i>United States v. Phillips</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3IS9G?jcsearch=219%20f%203d%20404&amp;summary=yes#jcite">219 F.3d 404</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3IS9G?jcsearch=219%20f%203d%20404&amp;summary=yes#jcite">409</a> (5th Cir. 2000).
"The residual hearsay exception is to be used only rarely, in truly
exceptional cases." <i>United States v. Walker</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X12BVN6003?jcsearch=410%20f%203d%20754&amp;summary=yes#jcite">410 F.3d 754</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X12BVN6003?jcsearch=410%20f%203d%20754&amp;summary=yes#jcite">757</a> (5th
Cir.2005) (citations and internal quotation marks omitted). To admit
evidence under the residual hearsay rule, there must be at least
circumstantial guarantees of trustworthiness. <i></i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X12BVN6003?jcsearch=410%20F.3d%20754&amp;summary=yes#jcite">Id. at 758</a>. The Fifth Circuit
has found there are equivalent circumstantial guarantees of trustworthiness
when the declaration is made under oath and the declarant is subject to the
penalties of perjury, the testimony was preserved on videotape, and the
witnesses were subject to cross-examination. <i><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X12BVN6003?jcsearch=410%20F.3d%20754&amp;summary=yes#jcite">Id</a>.</i> Here, Tognoni made a
written statement under penalty of perjury, but was never subjected to
cross-examination, which may be enough under Fifth Circuit law to guarantee
trustworthiness. However, even if it is trust-worthy, this is not an
exceptional case and thus does not warrant the residual hearsay exception.
<i>See Ortho-McNeil Pharm., Inc. v. Mylan Labs., Inc.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X18N34Q003?jcsearch=520%20f%203d%201358&amp;summary=yes#jcite">520 F.3d 1358</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X18N34Q003?jcsearch=520%20f%203d%201358&amp;summary=yes#jcite">1364</a>
(Fed. Cir.2008).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> Although the properties of the two agents were known independently,
Parma does not give any indication that the combination of the two produced
any benefit beyond those experienced when each agent is taken alone.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> Raskin teaches that sumatriptan can be used as an anti-migraine
without the concurrent use of anti-nausea agents. J.A.241903.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> The district court considered whether the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> was obvious is
light of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X300O044I8J?jcsearch=usp%206060499&amp;summary=yes#jcite">499 patent</a> combined with the Bandelin article that describes
how to create and the advantages of multilayer tablets. <i>Pozen</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1H0OT2003?jcsearch=800%20F.%20Supp.%202d%20789&amp;summary=yes#jcite">800 F.Supp.2d at 820</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1000" name="fn1000">[fn10]</a></span> <i>See infra</i> part C(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1100" name="fn1100">[fn11]</a></span> To establish literal infringement "every limitation set forth in a
claim must be found in an accused product, exactly." <i>Southwall Techs., Inc.</i>
<i>v. Cardinal IG Co.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X39LJ6?jcsearch=54%20f%203d%201570&amp;summary=yes#jcite">54 F.3d 1570</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X39LJ6?jcsearch=54%20f%203d%201570&amp;summary=yes#jcite">1575</a> (Fed.Cir.1995). The parties do not
contest literal infringement in this appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1200" name="fn1200">[fn12]</a></span> Par's ANDA states:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Most of our experiments were targeted to match the in-vitro dissolution
profile of the individual brands. Naproxen Sodium, is poorly soluble in
lower pH conditions, and tends to form a gel like matrix and thereby retard
the release of co-administered drugs. Our primary objective is to develop a
formulation having minimal effect of Naproxen Sodium over Sumatriptan
Succinate dissolution, thereby having release profiles independent of each
other in all the pH conditions. . . .
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A.157602.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1300" name="fn1300">[fn13]</a></span> Comparing DRL's dissolution profile of its ANDA product to Table 7 in
the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a>, which shows the dissolution profile of sumatriptan in a
bilayer tablet, Pozen's expert, Dr. Williams, opined that the dissolution
results in the table were almost the same as those in DRL's ANDA product.
J.A.6063-64.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1400" name="fn1400">[fn14]</a></span> In <i>Adams Respiratory</i> the requirement was "at least 3500 units" and
the accused product had 3493.38 units, within 0.189% of the claimed minimum.
<i>Adams Respiratory</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1DTP52003?jcsearch=616%20f%203d%201283&amp;summary=yes#jcite">616 F.3d at 1291</a>. In <i>Abbott Laboratories</i>, the claim
required between 68.8% and 94.5% by weight of a component, and the accused
product had 95% of that component. <i>Abbott Laboratories v. Dey L.P.</i>,
<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X4ITTB?jcsearch=287%20f%203d%201097&amp;summary=yes#jcite">287 F.3d 1097</a>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X4ITTB?jcsearch=287%20f%203d%201097&amp;summary=yes#jcite">1107</a> (Fed. Cir.2002).
</p></div>
</div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  CLEVENGER, Circuit Judge, dissenting-in-part.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I join the court's opinion in all respects but one. The District Court
erred in finding infringement of claim 2 of the `<a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3GOC4140OJ?jcsearch=usp%207332183&amp;summary=yes#jcite">183 patent</a> under the
doctrine of equivalents, and the court today errs in sustaining the judgment
of the District Court on this issue.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Claim 2 calls for a multilayer pharmaceutical tablet comprising naproxen
and a triptan wherein "substantially all of said triptan is in a first layer
of said tablet and substantially all of said naproxen is in a second,
separate layer." This claim language begged the question of how much by
volume of both naproxen and triptan less than 100% is "substantially all."
The District Court answered the question, construing "substantially all"
without objection <span CLASS="page_no" data-cite="2012 bl 251324 p 17" data-cite-type="Bloomberg" data-cite-pageno="17" data-primary-citation="">[***17]</span> to mean:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      "[A]t least 90%, and preferably greater than 95%, of the total
    triptan present in the tablet is "included within one distinct layer
    and at least 90%, and preferably greater than 95%, of the naproxen
    present in the tablet is included within a second distinct layer."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
The accused products do not literally meet the "substantially all"
limitation. That is why the patentee could not assert literal infringement
of claim 2, and why he was forced to rely on the doctrine of equivalents to
establish infringement. The actual composition of the claimed and accused
tablets, with regard to the "substantially all" limitation, is shown on the
following chart.
<span CLASS="page_no" data-cite="696 f 3d 1173" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1173" data-primary-citation="696 F.3d 1151">[*1173]</span> 
</p></div>
<pre>
                     <b>Claimed Product</b>                        <b>Par's ANDA product</b>                               <b>DRL's ANDA product</b>

<b>Layer 1</b>  &gt;90% total amt. of sumatriptan,         -100% total amt. of sumatriptan,          -85% total amt. of sumatriptan
         &lt;10% total amt. of naproxen             -15% total amt. of naproxen (granules)
<span CLASS="page_no" data-cite="104 uspq 2d 1986" data-cite-type="ReporterOfDecisions" data-cite-pageno="1986" data-primary-citation="104 U.S.P.Q.2d 1969">[**1986]</span> <b>Layer 2</b>  &gt;90% total amt. of naproxen,            -85% total amt. of naproxen               -100% total amt. of naproxen (granules),
         &lt;10% total amt. of sumatriptan                                                    -15% total amt. of sumatriptan (sprayed on granules)
</pre>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As shown in the table above, each of the Par and DRL products includes one
more or less "pure" layer meeting the "substantially all" limitation as
defined by the District Court. Par's product has substantially all the
required triptan in one layer along with 15% of the tablet's naproxen, but
the second Par layer has less than 90% of naproxen. So the question is
whether 85% of naproxen is equivalent to 90%, when "substantially all" means
"at least 90% and preferably greater than 95%."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  DRL's product is also designed to avoid the "substantially all"
limitation. It has substantially all the required naproxen in one layer,
along with 15% of the triptan, but the second DRL layer has only 85% of the
total triptan in the product. So, again, the question is whether 85% can be
"substantially all" given the District Court's construction of the
limitation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Pozen candidly admits in its brief to this court that the District Court
never directly addressed the question of whether a layer containing 85% of a
necessary ingredient is an equivalent of a layer containing at least 90% and
preferably 95% of the necessary ingredient. And Pozen says it does not argue
that 85% can be a numerical equivalent of 90%. Instead, Pozen argues that
the District Court properly elided the numeric equivalence issue by asking
only if the accused products had an "equivalent of a second layer" which
could be viewed as containing substantially all of the required ingredient.
Pozen and the District Court both see the "substantially all" limitation as
requiring the tablet to have one more or less pure layer, and not an actual
second layer but an "equivalent" second layer that could be said to be
equivalent to a more or less pure layer even if it failed to contain
substantially all of the required ingredient. In short, Pozen and the
District Court used the notion of an equivalent layer simply to avoid
answering the question of whether 85% is the equivalent of 90% or preferably
95%.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Even if the equivalent layer notion has merit, it still cannot be
disconnected from the language of the claim. <span CLASS="page_no" data-cite="2012 bl 251324 p 18" data-cite-type="Bloomberg" data-cite-pageno="18" data-primary-citation="">[***18]</span> The equivalent layer would, in
any event, have to be the equivalent of a more or less pure layer, i.e., one
with at least 90% and preferably 95% of the required ingredient in it. How
can a layer with only 85% of the necessary ingredient in it be an equivalent
of a layer with at least 90% and preferably 95% of the required ingredient
in it?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The District Court, with no contest from Pozen, recognized that
"substantially all" inherently contains a range from something less than
100% up to 100%. Rather than leave the inherent equivalent range embedded in
the claim language, the District Court put boundaries on the claim language.
"Substantially all" means at least 90%'and preferably 95%. The defendants
cite our precedent, including <i>Moore</i>
<span CLASS="page_no" data-cite="696 f 3d 1174" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1174" data-primary-citation="696 F.3d 1151">[*1174]</span> 
<i>U.S.A., Inc. v. Standard Register Co.</i>, <a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X3FMA8?jcsearch=229%20f%203d%201091&amp;summary=yes#jcite">229 F.3d 1091</a> (Fed.Cir.2000), for the
proposition that the spread from 85% to 90% is too great to be an
equivalent. Pozen appreciates the force of those cases, but argues they are
inapplicable here because the District Court did not answer the numeric
equivalence question but instead turned the infringement decision on a
flawed layer equivalence notion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In my view, the District Court erred by not asking itself if under claim 2
a layer, viewed from the outside or from the inside, can be equivalent if is
numerically none-quivalent. It cannot. The majority states that "a
reasonable person could determine that a tablet layer with 85% of the agent
is within the scope of the doctrine of equivalents." Respectfully, I
disagree.
</p></div>
<!--BBLS DD 1736749744131-->

</div>
</td>
<td align='left' class='fluidRightColumn ' id='fluid_right_column' valign='top'>
<div class='clearfix printHide sideBar'>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1IHF5K003/history">Direct History (5)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1IHF5K003/analysis">Case Analysis (8)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1IHF5K003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
8
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Order Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Pharmaceutical Manufacturing</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1Q6M17BCN82">11-01584 (Fed. Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1Q6M17BCQ82">11-01585 (Fed. Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/81f7e21f769d735614e58c05e1fd6833/document/X1Q6M17BCRO2">11-01586 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Patent Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
</td>
</tr>
</table>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/81f7e21f769d735614e58c05e1fd6833/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "81f7e21f769d735614e58c05e1fd6833";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYe7ff1f&previousPageId=&previousActivityInstanceId=ENTITY9f3287&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:25:48-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1IHF5K003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY9f3287&previousPageId=&previousActivityInstanceId=ENTITY5ad504&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:25:44-05:00';
FLUID_LAYOUT="true";
FULL_DOC_ID = 'X1IHF5K003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1IHF5K003";
$('#page_loader').show().spin();
JUDGE_IDS=["1850676","2530367","4141613"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
